Rocket Pharmaceuticals, Inc.

Worth knowing

• Shareholders being diluted. Shares outstanding up 39% from December 2022 to July 2026.

  Rocket Pharmaceuticals had 39% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Rocket Pharmaceuticals had 39% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

• Cash exceeds market value plus debt. Its cash is worth more than its market value plus debt.

  Rocket Pharmaceuticals's cash is larger than its market value and debt combined (enterprise value at or below zero). The market is valuing the operating business at nothing or less, which is rare.Rocket Pharmaceuticals's cash is larger than its market value and debt combined. The market is valuing the operating business at nothing or less, which is rare.

• Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

  Relative to its free cash flow, Rocket Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

• Loss over 12 months, profit last quarter. Lost money in the 12 months to June 2026, but made a $123M profit in the quarter to June 2026.

  Rocket Pharmaceuticals reported a net loss over the last twelve months, but its most recent quarter was profitable ($123M). One quarter isn't a trend, but it's closer to profitability than the 12-month figure suggests.